Rythmol SR

See also: Generic Rythmol

Rythmol SR is a brand name of propafenone, approved by the FDA in the following formulation(s):

RYTHMOL SR (propafenone hydrochloride - capsule, extended release; oral)

• 
  Manufacturer: GLAXOSMITHKLINE LLC
  
  Approval date: September 4, 2003
  
  Strength(s): 225MG ^[AB], 325MG ^[AB], 425MG ^[RLD][AB]

Has a generic version of Rythmol SR been approved?

A generic version of Rythmol SR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Rythmol SR and have been approved by the FDA:

propafenone hydrochloride capsule, extended release; oral

• 
  Manufacturer: PAR PHARM
  
  Approval date: October 18, 2010
  
  Strength(s): 225MG ^[AB], 325MG ^[AB], 425MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rythmol SR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Delayed release microtablet of .beta.-phenylpropiophenone derivatives
  Patent 5,681,588
  Issued: October 28, 1997
  Inventor(s): Kolter; Karl & Fricke; Helmut & Buehler; Volker & Mueller-Peltzer; Herbert
  Assignee(s): Knoll Aktiengesellschaft
  A cylindrical delayed release tablet with a convex or flat upper side and lower side is provided, along with a method for its production and a gelatin capsule containing 3-200 tablets of the same having identical or different release rates, wherein the tablet if made of .beta.-phenylpropiophenone derivatives of the formula I as active ingredient ##STR1## where R is n-propyl or 1,1-dimethylpropyl, and their pharmacologically acceptable salts, wherein the tablet has a height and diameter that are both, independently of one another, 1-3 mm, the active ingredient content is in the range from 81-99.9% of the weight of the microtablet, (but not taking into account the weight of any coating which is present, the active ingredient density is greater than 1, the release of active ingredient in the USP paddle method at 50 rpm is 80% as a maximum after 3 hours and as a minimum after 24 hours, the release rate is virtually independent of the pressure when compressing the tablets, and the tablet contains no release-delaying ancillary substance but can contain 0.1-5% by weight of a lubricant and 0-18.9% by weight of other conventional ancillary substances.
  
  Patent expiration dates:
  
  
  • October 28, 2014
    
  
  

See also...

• Rythmol SR Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Rythmol SR Consumer Information (Cerner Multum)
• Rythmol SR Advanced Consumer Information (Micromedex)
• Propafenone Consumer Information (Wolters Kluwer)
• Propafenone Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Propafenone Consumer Information (Cerner Multum)
• Propafenone Advanced Consumer Information (Micromedex)
• Propafenone Hydrochloride AHFS DI Monographs (ASHP)